Anatara Lifesciences (ASX:ANR) has announced the appointment of Steven Lydeamore as its CEO.
The company is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.
Anatara's Chair, Sue MacLeman, said the appointment is a key step in its development and transition to its focus on human health.
“We are very fortunate to have attracted someone of Steven’s calibre to lead Anatara at this important stage of the Company’s journey," said Ms MacLeman.
"Steve has demonstrated through his previous roles that he has the ability to successfully commercialise products on a global scale, driving growth and shareholder value.
"He has a deep understanding of the human health space and brings a strong track record of success in sales and marketing; research and development, business development, mergers and acquisitions, manufacturing and finance spanning Asia Pacific, Europe, Latin America and North America and will be key in leading the next phase of Anatara’s growth.
“On behalf of the Board, I would also like to thank Dr Tracie Ramsdale, who has been serving as Interim CEO since May 2018. Tracie will revert to her previous role of Non-Executive Director upon Steve’s commencement.”
Mr Lydeamore has 26 years of international experience in the pharmaceutical industry, working in Australia, the US and Canada.
His experience extends to sales and marketing, research and development, business development, mergers and acquisitions, manufacturing and finance, including involvement in the commercial development of numerous consumer products.
He spent 11 years working for Canada’s largest pharmaceutical company, Apotex, in a variety of roles including Vice President Global Business Development, Chief Business Officer and Managing Director of Apotex International Inc.
In his most recent role with Apotex, Mr Lydeamore was President of Apobiologix, a subsidiary responsible for the development of manufacturing and global commercialisation of biosimilars. He was responsible for more than 150 employees and net sales of $100 million.
He returned to Australia in August 2017 to take up the role of Chief Financial Officer for Bionomics.
Before working for Apotex, Mr Lydeamore worked in various finance roles for F.H. Faulding in Australia over a ten year period followed by four years in the US with Mayne Pharma (USA).
Mr Lydeamore said, “I am delighted to join Anatara. With strong intellectual property and a talented and passionate team, Anatara has a solid base for building a valuable business in the area of gastrointestinal health”.